Skip to main content

Table 2 Comparison of baseline characteristics of patients in the ETNA-AF-Europe registry and ENGAGE AF-TIMI 48 trial

From: Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

  ETNA-AF-Europe N = 13,638 ENGAGE AF-TIMI 48a Corresponding ETNA-AF countriesb N = 2123
Age (y), mean (SD) 73.6 (9.52) 72.7 (8.09)
By age sub-groups, n (%)
  < 65 years 2096 (15.4) 344 (16.2)
 65–75 years 4598 (33.7) 764 (36.0)
  ≥ 75 years 6939 (50.9) 1015 (47.8)
Male, % 56.6 62.4
BMI (kg/m2), mean (SD) 28.1 (5.14) 29.8 (5.39)
Weight (kg), mean (SD) 81.0 (17.34) 85.4 (17.47)
eCrCl (mL/min), mean (SD) 69.4 (24.23) 75.5 (28.96)
CHADS2, mean (SD) 1.7 (1.07) 2.8 (0.93)
CHA2DS2-VASc, calculated, mean (SD) 3.1 (1.40) 4.2 (1.31)
HAS-BLED, mean (SD) 2.6 (1.13) 1.6 (0.92)
Hypertension, % 76.9 92.4
Diabetes, % 21.9 39.1
Myocardial infarction, % 4.3 2.9
Ischaemic stroke, % 5.9 15.5
Transient ischaemic attack, % 3.3 11.9
Congestive heart failure, % 5.8 48.2
Paroxysmal AF, % 53.6 26.6
Persistent AF, % 24.4 24.1
Permanent AF, % 19.6 49.4
Renal disease (including dialysis), % 27.0 11.9
  1. amITT
  2. bBelgium, Switzerland, Germany, Spain, United Kingdom, Italy, Netherlands, Portugal
  3. % values are based on non-missing data
  4. AF atrial fibrillation, BMI body mass index, CHADS2 Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke (double weight), eCrCl estimated creatinine clearance (Cockcroft-Gault), ENGAGE AF-TIMI 48 study Effective aNticoaGulAtion with Factor Xa next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48, ETNA-AF Edoxaban Treatment in routine cliNical prActice, mITT modified intent-to-treat, SD standard deviation